<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03343418</url>
  </required_header>
  <id_info>
    <org_study_id>3962.13.087</org_study_id>
    <nct_id>NCT03343418</nct_id>
  </id_info>
  <brief_title>Effects of Prophylactic Desmopressin on Blood Coagulation Parameters in Heart Valve Surgery</brief_title>
  <official_title>Placebo-Controlled, Randomized, Double-Blind Trial of Prophylactic Desmopressin in Heart Valve Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Coracao</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluate the effect of prophylactic desmopressin on blood
      coagulation parameters and postoperative bleeding in patients undergoing valve cardiac
      surgery with cardiopulmonary bypass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with important valve disorders may evaluate with coagulopathy induced by mechanical
      effects (valvular stenosis or valvular insufficiency). Furthermore, frequently is required
      prophylactic use of antiplatelet drugs due to myocardial remodeling and antiarrhythmic
      conditions that may be associated. Patients with severe aortic stenosis may also acquired von
      Willebrand disease type 2A due to proteolysis of vonWillebrand factor. Despite of this, the
      treatment of valve disorders often requires cardiac surgery with cardiopulmonary bypass. On
      average 50 to 60% of patients undergoing cardiac surgery receive blood tranfusions. Blood
      cell transfusion is an independent risk factor for increased morbidity and mortality in
      critically ill patients. The use of desmopressin seems beneficial only in patients with
      congenital or acquired platelet dysfunction. In general population, such use is not validated
      due to inconclusive results of researches.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in coagulation parameters</measure>
    <time_frame>Coagulation parameters will be performed: T0: preoperative period; T1 - 2 hours after desmopressin or placebo administration; T2 - 24 hours after desmopressin or placebo administration</time_frame>
    <description>Laboratory variables: Activated partial thromboplastin time [(aPTT) seconds], prothrombin time [(PT) seconds], haematocrit (%), haemoglobin(g/dl), fibrinogen(mg/dL), D dimer (ng/L), factor VIII(%), Von Willebrand factor(%), ROTEM [(INTEM, EXTEM, FIBTEM) Clotting Time (CT) and Clot Formation Time (CFT) seconds, alpha angle (α º), Maximum Clot Firmness (MCF) mm ] and platelets aggregation (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative blood loss</measure>
    <time_frame>48 hours</time_frame>
    <description>Total chest tube drainage (mL) starting immediately after closure of the chest in the operating theater until 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>30 days</time_frame>
    <description>Number of units of red blood cells, fresh frozen plasma,platelets, cryoprecipitate in the operating theater and ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation for bleeding</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical ventilation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of vasoactive drugs</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical complications - renal failure, infection, myocardial ischemia, stroke</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>C.Surgical Procedure; Cardiac</condition>
  <condition>Blood Coagulation Disorders</condition>
  <arm_group>
    <arm_group_label>desmopressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this group receive desmopressin 0,3 microgram.kg-1 as an intravenous infusion given during 20 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to the control group will receive the infusion of 100 mL 0.9% saline (SF0,9%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmopressin</intervention_name>
    <description>Desmopressin is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given desmopressin 0,3 microgram.kg-1. After desmopressin infusion, bleeding treatment will follow the predefined standardized treatment regimen.</description>
    <arm_group_label>desmopressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 100 milliliters (mL) 0.9% saline (SF0,9%). After 0.9% saline infusion, bleeding treatment will follow the predefined standardized treatment regimen.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Valve cardiac surgery with cardiopulmonary bypass.

          -  Written informed consent

        Exclusion Criteria:

          -  Reoperative valve surgery

          -  Hematocrit &lt; 35%

          -  Ventricular dysfunction (EF &lt; 40%)

          -  Infection

          -  Body mass index &gt; 35

          -  Renal impairment (Creatinin &gt; 2mg/dL)

          -  Antiplatelet administration within 10 days preceding study surgery

          -  Participation in another interventional clinical study within 30 days

          -  Known or suspected hypersensitivity to the desmopressin

          -  Coagulopathy (INR &gt; 1.5)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Incor - Heart Institute - University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Galas FR, de Almeida JP, Fukushima JT, Vincent JL, Osawa EA, Zeferino S, Câmara L, Guimarães VA, Jatene MB, Hajjar LA. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: a randomized pilot trial. J Thorac Cardiovasc Surg. 2014 Oct;148(4):1647-55. doi: 10.1016/j.jtcvs.2014.04.029. Epub 2014 Apr 18.</citation>
    <PMID>24951020</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto do Coracao</investigator_affiliation>
    <investigator_full_name>Filomena R B G Galas</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Bleeding</keyword>
  <keyword>Valve Cardiac Surgery</keyword>
  <keyword>Desmopressin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

